Assessment of the Effectiveness of Updated Educational Materials on Prescribers' Knowledge and Behavior With Respect to Risks Associated With INSTANYL® Off-Label Use
The purpose of the Instanyl study is to learn how much doctors know and understand about Instanyl® before and after they receive updated educational information, including the risks of its unapproved use. In this study, the doctors will complete two surveys: one three months before they receive the updated educational information, and one about six months after they receive this information. They will answer questions about their prescribing behavior plus their knowledge of Instanyl® including any risks.
• Specialists of any of those medical specialties targeted for the EMs as agreed with each national competent authority. The foreseen specialties include the following (subject to changes after the EM distribution plan is completed and agreed with national competent authorities):
‣ Oncologists and oncoradiologists
⁃ Anaesthesiologists
⁃ Pain management prescribers
⁃ Palliative care prescribers
⁃ Internal medicine prescribers
⁃ General practitioner (GPs)
⁃ Other specialties may be locally included such as hematology. Current and potential prescribers may vary between country; thus, some countries may have modified lists of target specialties.
• Physicians who have prescribed Instanyl® in the past 12 months (pre-EM survey) or since the updated EMs (post-EM survey) and who intend to prescribe Instanyl® in the following months after each survey.